# Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies

> **NCT01242072** · PHASE1 · UNKNOWN · sponsor: **Alaunos Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Malignancy
- Cancer
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
- Testicular Cancer
- Thymoma
- Ovarian Cancer
- Osteosarcoma

## Interventions

- **DRUG:** palifosfamide-tris

## Key facts

- **NCT ID:** NCT01242072
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2012-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01242072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01242072, "Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01242072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*